Anti-urokinase-type plasminogen activator monoclonal antibodies inhibit the proliferation of human breast cancer cell lines in vitro

Tumor Biology

Volumn 19, Issue 4, 1998, Pages 229-237

  Abaza, Mohamed Salah I ^a,b   Narayan, Raj K ^a   Atassi, M Z ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Anti proliferative activity; Breast cancer cell lines; Monoclonal antibodies; Urokinase type plasminogen activator

Indexed keywords

MONOCLONAL ANTIBODY; UROKINASE;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL INVASION; CELL PROLIFERATION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0031870937     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000030012     Document Type: Article

References (47)

1. Orenstein NS, Buczynski A, Dvorake F: Cryptic and active plasminogen activator by line 100 tumor cells in culture Cancer Res 1983;43:1783-1789.
2. Persky B, Ostrowski LE, Pagast P, Ashan A, Schultz M: Inhibition of proteolytic enzymes in the in vitro amnion model for basement membrane invasion Cancer Res 1986;46:4129-4134.
3. Mignotti P, Robbins E, Rifkin DB: Tumor invasion through the human amniotic membrane- Requirement for a proteinase cascade. Cell 1986;47:487-498.
4. Buttler WB, Berlinski PJ, Hillman RM, Kelsey EH, Toenninges MM: Relation of in vitro properties to tumorigenicity for a series of sublines of the human breast cancer cell hue MCF-7. Cancer Res 1986;46:6339-6348.
5. Reich R, Thompson EW, Iwamoto Y, Martin G, Deason JR, Fuller GC, Miskin R: Effect of inhibitors of plasminogen activator, serine proteinases and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res 1988;48:3307-3312.
6. Alexancer CM, Werb Z: Extracellular matrix degradation; in Hay ED (ed): Cell Biology of Extracellular Matrix. New York, Plenum, 1991; pp 255-302.
7. Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 1991;64:327-336.
8. Mignatti P, Rifkin DB: Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993;73: 161-195.
9. Stetler-Stevenson WG, Aznavoorian S, Liotta LA: Tumor cell interactions with extracellular matrix during invasion and metastasis. Cell Biol 1993;9:541-573.
10. Dvorak HF: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315:1650-1659.
11. La Polt PS, Tsafriri A, Bicsak TA, Ny T, Hsueh AJW: Changes in tissue-type plasminogen activator levels during ovulation, oocyte maturation and early embryonic development; in Tsafrir A, Dekel N (eds): Follicular Development and Ovulatory Response. Rome, Ares-Serono Symposia, 1990, pp 159-168.
12. Feinberg RF, Kao LC, Haimowitz JE, Queenan JT Jr, Wun TC, Strauss JF III, Kliman HJ: Plasminogen activator inhibitor types 1 and 2 in human trophoblasts. Lab Invest 1989;61-20-26.
13. Danq K, Anderson PA, Grondahl-Hansen J, Kristensen P, Nielson LS, Skriver L: Plasminogen activator, tissue degradation and cancer. Adv Cancer Res 1985;44:139.
14. Goldfarb RH: Proteases in tumor invasion and metastasis; in Liotta LA, Hart IR (eds); Tumor Invasion and Metastasis. The Hague, Nijhoff, 1982, chap 22, pp 375-390.
15. Barrett JC, Sheela S: Plasminogen activator in metastasis; in Liotta LA, Hart IR (eds): Tumor Invasion and Metastasis. The Hague, Nijhoff, 1982, chap 21, pp 359-374.
16. Markus G: The role of hemostasis and fibrinolysis in the metastatic spread of cancer. Semin Thromb Hemost 1984;10:61.
17. Reich E: Activator of plasminogen: A widespread mechanism for generating localized extracellular proteolysis; in Rudden RW (ed): Biological Markers of Neoplasia: Basic and Applied Aspects. New York, Elsevier, 1978, pp 491-500.
18. Blasi F: Surface receptors for urokinase plasminogen activator. Fibrinolysis 1988;2:73-84.
19. Stump DC, Linjnen HR, Collen D: Purification and characterization of a novel low molecular weight form of single-chain urokinase-type plasminogen activator. J Biol Chem 1986;261:17120-17126.
20. Ichinose A, Kujikawa K, Suyama T: The activation of prourokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 1986;261:3486-3489.
21. Kobayashi H, Schmitt M, Goretzky L, Chucholowski N, Calvete J, Kramer M, Gunzler WA, Janicke F, Graeff H: Cathepsin B efficiently activates the soluble and tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (pro-uPA). J Biol Chem 1991;266:5147-5152.
22. Plow EF, Freany DE, Plescia J, Miles LA: The plasminogen system and cell surfaces: Evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol 1986;103:2411-2420.
23. Liotta LA, Goldfarb RH, Brundage R, Seigal GP, Terranova V, Garbisa S. Effect of plasminogen activator (urokinase), plasma and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 1981;41:4629.
24. Werb Z, Mainardi CL, Vater CA, Harris ED Jr: Endogenous activation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator. N Engl J Med 1973;296:1017.
25. Salo T, Liotta LA, Keiski-Oja J, Turpeenniemi-Hujanen T, Tryggvason K: Secretion of basement membrane collagen degrading enzyme and plasminogen activator by transformed cells - Role in metastasis. Int J Cancer 1982;30:669.
26. Suzumiya J, Hasui Y, Kohga S, Sumiyoshi A, Hashida S, Ishikawa E: Comparative study of plasminogen activator antigens in colonic carcinomas and adenomas. Int J Cancer 1988;42:627-632.
27. Sapping PA, Busso N, Belin D, Vassalli J-D: Increase of urokinase type plasminogen activator gene expression in human lung carcinomas. Cancer Res 1987;47:4043-4046
28. Grondahl-Hansen J, Christensen IB, Rosenquist C: High levels of urokinase type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993;53:2513-2521.
29. Janicke F, Schmitt M, Fache L, Ulm K, Harbeck N, Hofler H, Graeff H: Urokinase and its inhibitor PAI-1 are strong and independent prognostic factors in node negative breast cancer. Breast Cancer Res Treat 1993;24:195-208.
30. Foekens JA, Schmitt M, Van Putten WL, Petters AH, Bontenbal M, Janicke F: Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 1992;52:6101-6105
31. Foucre D, Bouchet C, Hacene K, Pourreau-Schneider N, Gentile A, Martin PM, Desplaces A, Oglobine J: Relationship between cathepsin D, urokinase and plasminogen activator inhibitors in malignant vs benign breast tumors. Br J Cancer 1991;64:926-932.
32. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ, Andreasen P: Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 1990;50:6827-6829.
33. Saito K, Nagashima M, Iwata M, Hamada M, Sumiyoshi K, Takada Y, Takada A: The concentration of tissue plasminogen activator and urokinase in plasma and tissues of patients with ovarian and uterine tumors. Thromb Res 1990;58:355-366.
34. Kirchheimer JC, Pfluger H, Ritschl P, Hienert G, Binder BR: Plasminogen activator activity in bone metastasis of prostatic carcinomas as compared to primary tumors. Invasion Metastasis 1985;5:344-355.
35. Abaza MSI, Shaban Fatma, Narayan RK, Atassi MZ: In vitro inhibition of human malignant brain tumor cell lines proliferation by antiurokinase-type plasminogen activator monoclonal antibodies. Br J Cancer, in press.
36. De Bruin PAF, Griffoen G, Verspaget HW, Verheijen JH, Lamers CBHW: Plasminogen activators and tumor development in human colon: Activity levels in normal mucosa, adenomatous polyps and adenocarcinomas. Cancer Res 1987;47: 4654.
37. Ossowski L, Reich E: Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 1983;35:611.
38. Duffy MJ: Do proteases play a role in cancer invasion and metastasis? Eur J Cancer Clin Oncol 1987;23: 583-589.
39. Zucker SA: A critical appraisal of the role of proteolytic enzymes in cancer invasion: Emphasis on tumor surface proteinases. Cancer Invest 1988;6:219-231.
40. Casslen B, Gustavsson B, Astedt B: Cell membrane receptors for urokinase plasminogen are increased in malignant ovarian tumors. Eur J Cancer 1991;27:1445-1448.
41. Blasi F, Vassali J-D, Danq K: Urokinase-type plasminogen activator: Proenzyme, receptor and inhibitors. J Cell Biol 1987;104:801-804.
42. Pollanen J, Stepens RW, Vaheri A: Plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res 1991;57:273-382.
43. Ossowski L: Invasion of connective tissue by human carcinoma cell lines: Requirement for urokinase, urokinase receptor, and interstitial collagenase. Cancer Res 1992;52: 6754-6760
44. Kirchheimer JC, Wojto J, Christ G, Binder BR: Proliferation of a human epidermal tumor cell line stimulated by urokinase. FASEB J 1987;1:125-128.
45. Rabbani SA, Desjardins J, Bell AW, Banville D, Goltzman D: An aminoterminal fragment of urokinase isolated from a prostate cancer cell line (OC-3) is mitogenic for osteoblast-like cells. Biochem Biophys Res Commun 1990;173:1058-1046.
46. Yasunaga C, Nakashima Y, Sueishi K: A role of fibrinolytic activity in angiogenesis. Quantitative assay using in vitro method. Lab Invest 1989;61:698-704.
47. Sato Y, Okamura K, Kohno K, Jakata T, Kumano M: Indispensable role of tissue-type plasminogen activator in growth factor dependent tube formation of human microvascular endothelial cells in vitro. Exp Cell Res 1993;204:223-229.